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Abstract
Human podoplanin (hPDPN), which binds to C- type lectin- like receptor- 2 
(CLEC- 2), is involved in platelet aggregation and cancer metastasis. The expres-
sion of hPDPN in cancer cells or cancer- associated fibroblasts indicates poor 
prognosis. Human lymphatic endothelial cells, lung- type I alveolar cells, and 
renal glomerular epithelial cells express hPDPN. Although numerous monoclonal 
antibodies (mAbs) against hPDPN are available, they recognize peptide epitopes 
of hPDPN. Here, we generated a novel anti- hPDPN mAb, LpMab- 21. To char-
acterize the hPDPN epitope recognized by the LpMab- 21, we established glycan- 
deficient CHO- S and HEK- 293T cell lines, using the CRISPR/Cas9 or TALEN. 
Flow cytometric analysis revealed that the minimum hPDPN epitope, in which 
sialic acid is linked to Thr76, recognized by LpMab- 21 is Thr76–Arg79. LpMab-
 21 detected hPDPN expression in glioblastoma, oral squamous carcinoma, and 
seminoma cells as well as in normal lymphatic endothelial cells. However, 
LpMab- 21 did not react with renal glomerular epithelial cells or lung type I 
alveolar cells, indicating that sialylation of hPDPN Thr76 is cell- type- specific. 
LpMab- 21 combined with other anti- hPDPN antibodies that recognize different 
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Introduction
Human podoplanin (hPDPN) is expressed in many can-
cers, including malignant gliomas, lung cancers, esophageal 
cancers, malignant mesotheliomas, testicular cancers, blad-
der cancers, and osteosarcomas [1–13], and the expression 
of hPDPN in cancer- associated fibroblasts contributes to 
poor prognosis [14–19]. Human PDPN (known as the 
platelet aggregation- inducing factor Aggrus) is involved 
in cancer metastasis [11, 20, 21]. We identified C- type 
lectin- like receptor- 2 (CLEC- 2) as an endogenous receptor 
of hPDPN [22, 23]. Moreover, our comparative crystal-
lographic studies of the hPDPN–CLEC- 2 complex [24] 
revealed that CLEC- 2 binds to hPDPN through residues 
Glu47 and Asp48 within its platelet aggregation-stimulating 
(PLAG) domain as well as to the α2- 6- linked sialic acid 
linked to Thr52.
Highly sensitive and specific anti-hPDPN mAb are 
required to clarify the physiological function of hPDPN 
in normal tissues and cancers. Although many anti- hPDPN 
mAbs are available, most react with the PLAG1-PLAG3 
of hPDPN [6, 25–29]. We previously established the origi-
nal technology to produce anti- glycopeptide mAbs 
(GpMabs) against hPDPN [30–39]. Here, we generated a 
novel anti- hPDPN mAb designated LpMab- 21 that rec-
ognizes a sialylated glycopeptide epitope.
Furthermore, to characterize the hPDPN epitope rec-
ognized by the LpMab- 21, we need glycan- deficient CHO- S 
or HEK- 293T cell lines. We report the establishment of 
glycan- deficient cell lines using the CRISPR/Cas9 or 
TALEN.
Materials and Methods
Cell lines, mice, and human tissues
As described in detail previously [36, 39], the cell lines 
LN229, HEK- 293T, NCI- H226, U- 2 OS, Met- 5A, Chinese 
hamster ovary (CHO)- K1, and P3U1 were obtained from 
the American Type Culture Collection (ATCC, Manassas, 
VA). The HSC- 2 and HSC- 4 cell lines were obtained from 
the Japanese Collection of Research Bioresources (JCRB) 
Cell Bank (Osaka, Japan). The MG- 63 cell line was obtained 
from the Cell Resource Center for Biomedical Research 
Institute of Development, Aging and Cancer Tohoku 
University (Miyagi, Japan). The LN319 cell line was pro-
vided by Prof. Kazuhiko Mishima (Saitama Medical 
University, Saitama, Japan) [40]. Human lymphatic 
endothelial cells (LECs), CHO- S cells, and PC- 10 cells 
were purchased from Cambrex Corp., East Rutherford, 
NJ, Thermo Fisher Scientific Inc., (Waltham, MA), and 
Immuno- Biological Laboratories Co., Ltd. (Gunma, Japan), 
respectively. LN229 and CHO- K1 cells were transfected 
with the hPDPN plasmids using Lipofectamine 2000 
(Thermo Fisher Scientific Inc.) according to the manu-
facturer’s instructions [30].
CHO- K1, CHO- K1/hPDPN, CHO- S, NCI- H226, PC- 10, 
and P3U1 cells were cultured in RPMI 1640 medium 
containing l- glutamine (Nacalai Tesque, Inc., Kyoto, 
Japan). LN229, LN229/hPDPN, LN319, HSC- 2, HSC- 4, 
and HEK- 293T cells were cultured at 37°C in a humidi-
fied atmosphere containing 5% CO2 in Dulbecco’s Modified 
Eagle’s Medium (DMEM) medium containing L- glutamine 
(Nacalai Tesque, Inc.) and 10% heat- inactivated fetal bovine 
serum (FBS) (Thermo Fisher Scientific Inc.). LECs were 
cultured in endothelial cell medium EGM- 2MV supple-
mented with 5% FBS (Cambrex Corp. East Rutherford, 
NJ). All media contained 100 units/mL of penicillin, 100 μg/
mL of streptomycin, and 25 μg/mL of amphotericin B 
(Nacalai Tesque, Inc.).
Three female BALB/c mice (4- week- old) were purchased 
from CLEA Japan (Tokyo, Japan) and were housed under 
pathogen- free conditions. The Animal Care and Use 
Committee of Tohoku University approved the animal 
experiments described herein.
The Tokyo Medical and Dental University Institutional 
Review Board and the Sendai Medical Center Review Board 
reviewed and approved the use of human cancer tissues. 
Written informed consent was obtained for using the 
human cancer tissue samples. Microarrays of normal human 
tissues were purchased from Cybrdi, Inc. (Frederick, MD).
Production of glycan- deficient or PDPN- 
knock out cell lines
The HEK- 293T/hPDPN- knockout (KO) cell line (PDIS- 2) 
and the LN319/hPDPN- KO cell line (PDIS- 6) were gener-
ated by transfection using CRISPR/Cas9 plasmids (Target 
ID: HS0000333287) that target PDPN (Sigma- Aldrich, St. 
Louis, MO). Plasmids were transfected, using a Gene Pulser 
Xcell electroporation system (Bio- Rad Laboratories Inc., 
Berkeley, CA) [31, 34]. PDIS- 2 and PDIS- 6 cells were 
screened using the NZ- 1 mAb [5]. The cell lines CHO- S/
GnT- 1- KO (PDIS- 9) and CHO- S/SLC35A1- KO (PDIS- 14) 
were generated by transfecting TALEN or CRISPR/Cas9 
plasmids, which target hsMgat1 (Wako Pure Chemical 
Industries Ltd., Osaka, Japan) and SLC35A1 (Target ID: 
HS0000168432; Sigma- Aldrich), respectively, using a Gene 
Pulser Xcell electroporation system. The cell lines HEK- 
293T/GnT- 1- KO (PDIS- 1 or PDIS- 12) and HEK- 293T/
SLC35A1- KO (PDIS- 22) were generated by transfecting 
TALEN or CRISPR/Cas9 plasmids, which target hsMgat1 
(Wako Pure Chemical Industries Ltd., Osaka, Japan) and 
SLC35A1 (Target ID: HS0000168432; Sigma- Aldrich), 
respectively, using a Gene Pulser Xcell electroporation 
system. PDIS- 1, PDIS- 9, and PDIS- 12 cells were screened 
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using leukoagglutinin from Phaseolus vulgaris (L- PHA). 
PDIS- 14 and PDIS- 22 cells were screened using Maackia 
amrensis Lectin II (MAL- II). PDIS- 9 and PDIS- 14 cells 
were transfected with the human PDPN plasmids using 
Lipofectamine LTX (Thermo Fisher Scientific Inc.) accord-
ing to the manufacturer’s instructions. Glycan- deficient 
cell lines were cultured in RPMI 1640 medium.
Generation of deletion mutants
Amplified hPDPN cDNA was subcloned into a pCAG- 
Ble(Zeo) vector (Wako Pure Chemical Industries Ltd.) 
with a MAP- tag, detected by PMab- 1 [41, 42], which was 
added to the N- terminus using the In- Fusion HD Cloning 
Kit (Clontech, Palo Alto, CA). Deletion mutants of hPDPN 
were generated using the primers as follows:






















CHO- K1 cells were transfected with these plasmids using 
Lipofectamine LTX (Thermo Fisher Scientific Inc.). Deletion 
mutants were cultured in RPMI 1640 medium containing 
l- glutamine (Nacalai Tesque, Inc.) and 10% heat- inactivated 
FBS at 37°C in a humidified atmosphere containing 5% 
CO2. Stable transfectants of CHO- K1/ssMAP- hPDPNdN 
mutants were selected by culturing them in medium con-
taining 0.5 mg/mL Zeocin (InvivoGen, San Diego, CA).
Production of point mutants
The amplified hPDPN cDNA was subcloned into a pcDNA3 
vector (Thermo Fisher Scientific Inc.), and a FLAG epitope 
tag was added to the C- terminus. Substitutions of amino 
acid residues to Ala or Gly in the hPDPN sequence were 
performed, using a QuikChange Lightning site- directed 
mutagenesis kit (Agilent Technologies Inc., Santa Clara, 
CA) using oligonucleotides containing the desired muta-
tions. CHO- S or CHO- K1 cells were transfected with the 
plasmids using a Gene Pulser Xcell electroporation system 
(Bio- Rad Laboratories Inc.). Point mutants were cultured 
in RPMI 1640 medium containing l- glutamine.
Hybridoma production
Three 4- week- old female BALB/c mice were immunized by 
intraperitoneal (i.p.) injection of 1 × 108 LN229/hPDPN 
cells together with Imject Alum (Thermo Fisher Scientific 
Inc.) [30]. A booster injection was administered i.p. 2 days 
before the mice were euthanized by cervical dislocation. 
Spleen cells were harvested and fused with P3U1 cells using 
PEG1500 (Roche Diagnostics, Indianapolis, IN). The hybri-
domas were cultured in RPMI 1640 medium containing 
hypoxanthine, aminopterin, and thymidine selection medium 
supplement (Thermo Fisher Scientific Inc.). The culture 
supernatants were screened, using an enzyme- linked immu-
nosorbent assay (ELISA) and recombinant human PDPN 
purified from LN229/hPDPN cells [30]. Proteins (1 μg/mL) 
were immobilized on Nunc Maxisorp 96- well immunoplates 
(Thermo Fisher Scientific Inc.) for 30 min. After blocking 
with 1% bovine serum albumin (BSA) in 0.05% Tween20/
phosphate- buffered saline (PBS) (Nacalai Tesque, Inc.), the 
plates were incubated with culture supernatants, followed 
by the addition of peroxidase- conjugated anti- mouse IgG 
diluted 1:2000 (Dako; Agilent Technologies, Inc.). The enzy-
matic reaction was conducted using a 1- Step Ultra TMB- 
ELISA (Thermo Fisher Scientific Inc.). Optical density was 
measured at 655 nm using an iMark microplate reader 
(Bio- Rad Laboratories Inc.).
Flow cytometry
Cell lines were harvested after brief exposure to 0.25% 
Trypsin/1 mmol/L EDTA (Nacalai Tesque, Inc.). After 
washing with 0.1% BSA in PBS, the cells were treated 
with primary mAbs for 30 min at 4°C, followed by treat-
ment with Oregon Green 488- conjugated to goat anti- 
mouse IgG or anti- rat IgG (Thermo Fisher Scientific Inc.). 
Fluorescence data were acquired using a Cell Analyzer 
EC800 (Sony Corp., Tokyo, Japan).
Immunohistochemical analyses
Four- μm- thick tissue sections were deparaffinized using xylene 
and rehydrated. After antigen retrieval, (autoclaving using 
citrate buffer, pH 6.0), sections were incubated with 1 μg/
mL of LpMab- 21 for 1 h at room temperature, and immu-
nocomplexes were treated with an Envision+ Kit (Dako) 
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for 30 min, color was developed using 3, 3- diaminobenzidine 
tetrahydrochloride (DAB, Dako) for 5 min. Sections were 
then counterstained with hematoxylin (Wako Pure Chemical 
Industries Ltd.).
Results
Generation of a novel anti- hPDPN mAb 
(LpMab- 21)
We first immunized one mouse with the LN229/hPDPN, 
and harvested spleen cells were fused with P3U1. The ELISA 
screening was performed with supernatants from 960 hybri-
domas. Among 135 ELISA- positive wells, 19 wells reacted 
with LN229/hPDPN, but not with LN229 in flow cytometry. 
We performed single- cell cloning for 19 wells by limiting 
dilution, and could obtain 14 hybridomas. Among them, 
we previously reported five clones including LpMab- 10, 
LpMab- 12, LpMab- 13, LpMab- 17, and LpMab- 19 [30–36, 
38, 39, 43]. In this study, we newly report LpMab- 21 (IgG2a, 
kappa), which was the first IgG2a mouse anti- hPDPN mAb 
in our study. Flow cytometry revealed that LpMab- 21 reacted 
with LN229/hPDPN cells but not with LN229 cells that 
were hPDPN- negative (Fig. 1A). LpMab- 21 detected endog-
enous hPDPN, which is expressed in the glioblastoma cell 
line LN319, but not in LN319/hPDPN- KO cells (PDIS - 6), 
indicating that LpMab-21 is specific against hPDPN 
(Fig. 1B).
LpMab- 21 detected the expression of hPDPN in normal 
cells such as a lymphatic endothelial cell (LEC) and a 
mesothelial cell line Met-5A (Fig. 2A). The positive- control 
LpMab- 17 reacted with LEC and Met-5A (Fig. 2B). 
LpMab- 21 detected endogenous hPDPN, which is expressed 
in the kidney epithelial cell line HEK- 293T, but not in 
HEK- 293T/hPDPN- KO cells (PDIS-2), indicating that 
LpMab-21 is specific against hPDPN (Fig. 2C).
We next investigated whether LpMab- 21 was suitable 
for immunohistochemical analyses (Fig. 3). Consistent 
with the expression of hPDPN by lymphatic endothelial 
cells [44], LpMab- 21 reacted with lymphatic endothelial 
cells of the esophagus (Fig. 3A), colon (Fig. 3C), lung 
Figure 1. Flow cytometric analysis using LpMab- 21 to detect hPDPN 
expression. (A) LN229 and LN229/hPDPN cells were treated with 
LpMab- 21 (1 μg/mL, red) or PBS (black) for 30 min at 4°C followed by 
treatment with anti- mouse IgG- Oregon green. (B) LN319 and 
LN319/hPDPN- KO cells (PDIS- 6) were treated with LpMab- 21 (1 μg/mL, 
red) or PBS (black) for 30 min at 4°C followed by addition of anti- mouse 
IgG- Oregon green. Fluorescence data were collected using a Cell Analyzer 
EC800. Geometric Mean was described. hPDPN, Human podoplanin.
Figure 2. Flow cytometric analysis using LpMab- 21 to detect hPDPN 
expression in normal cells. (A) Human lymphatic endothelial cell (LEC) 
and human mesothelial cells (Met- 5A) were reacted with LpMab- 21 
(1 μg/mL, red) or PBS (black) for 30 min at 4°C, followed by treatment 
with anti- mouse IgG- Oregon green. (B) LEC and Met- 5A cells were 
treated with LpMab- 17 (1 μg/mL, red) or PBS (black) for 30 min at 4°C, 
followed by treatment with anti- mouse IgG- Oregon green. (C) The 
human embryonic renal epithelial cell line (HEK- 293T) and HEK- 
293T/hPDPN- KO cells (PDIS- 2) were reacted with LpMab- 21 (1 μg/mL, 
red) or PBS (black) for 30 min at 4°C, followed by addition of anti- 
mouse IgG- Oregon green. Fluorescence data were acquired using a Cell 
Analyzer EC800. Geometric Mean was described. LEC, lymphatic 
endothelial cell.
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(Fig. 3D), kidney (Fig. 3E), and rectum (Fig. 3F). LpMab- 21 
detected hPDPN expressed by basal keratinocytes of the 
esophagus (Fig. 3A) and myoepithelial cells of breast 
glands (Fig. 3B). In contrast, LpMab- 21 did not detect 
hPDPN expression in type I alveolar cells of lung (Fig. 3D) 
and podocytes of the renal glomerulus (Fig. 3E). These 
results indicate that the epitope recognized by LpMab- 21 
is tissue-specific [45].
Flow cytometric and immunohistochemical 
analyses using LpMab- 21 to detect hPDPN 
expression in cancers
PDPN is expressed by cancers such as brain tumors, 
mesotheliomas, oral cancers, lung cancers, esophageal 
cancers, testicular cancers, and osteosarcoma [1, 9, 32]. 
Flow cytometry using LpMab- 21 detected endogenous 
expression of PDPN by the human cancer cell lines as 
follows: mesothelioma, NCI- H226; oral squamous cell 
carcinoma, HSC- 2 and HSC- 4; squamous cell carcinoma 
of the lung, PC- 10; and human osteosarcoma, U- 2 OS 
and MG- 63 (Fig. 4A). LpMab- 17 detected PDPN expres-
sion by all cell lines (Fig. 4B).
Immunohistochemical analysis (with or without antigen 
retrieval), using LpMab- 21 detected membrane- associated 
PDPN expression in the human tumor tissues as follows: 
glioblastoma (Fig. 5A), oral squamous cell carcinoma 
(OSCC) (Fig. 5B), and a seminoma (Fig. 5C). LpMab- 21 
reacted with lymphatic endothelial cells in OSCC tissues 
(Fig. 5D), but not with vascular endothelial cells (Fig. 5D), 
demonstrating that LpMab- 21 is useful for detecting lym-
phatic endothelial cells in cancer tissues.
Characterization of LpMab- 21 using glycan- 
deficient cell lines
Human PDPN is O- glycosylated, but not N- glycosylated 
[6, 24, 46–48]. In this study, we generated a 
Figure 3. Immunohistochemical analysis using LpMab- 21 to detect PDPN expression in normal human tissues. Tissues harvested from the esophagus 
(A), breast (B), colon (C), lung (D), kidney (E), and rectum (F). After antigen retrieval procedure, sections were incubated with 1 μg/mL of LpMab- 21, 
reacted with the Envision+ kit, color was developed, using DAB, and samples were then counterstained with hematoxylin. Arrowheads, lymphatic 
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GnT- 1- knockout (KO) cell line (CHO- S/GnT- 1- KO, 
PDIS- 9) and a CMP- sialic acid transporter 
(SLC35A1)- KO cell line (CHO- S/SLC35A1- KO, PDIS- 14) 
by transfecting them with TALEN and CRISPR/Cas9 
plasmids, respectively (Table 1). PDIS- 9 and PDIS- 14 
cells were screened using leukoagglutinin from Phaseolus 
vulgaris (L- PHA) and MAL- II, respectively. When we 
used the hPDPN expression vector to transfect PDIS- 9 
and PDIS- 14 cells, we found that LpMab- 21 reacted 
with CHO- S/hPDPN and PDIS- 9/hPDPN cells but not 
with PDIS- 14/hPDPN cells (Fig. 6A and B). We further 
generated a GnT- 1-KO cell line (HEK- 293T/GnT- 1- KO, 
PDIS- 1 or PDIS- 12) and a CMP- sialic acid transporter 
(SLC35A1)- KO cell line (HEK- 293T/SLC35A1- KO, 
PDIS- 22) by transfecting them with TALEN and CRISPR/
Cas9 plasmids, respectively (Table 1). PDIS- 1 and PDIS- 
12 cells were screened using L- PHA. PDIS- 22 cells were 
screened using MAL- II. We found that LpMab- 21 reacted 
with HEK- 293T, PDIS- 1, and PDIS- 12 cells but not with 
PDIS- 22 cells (Fig. S1). These results indicate that the 
hPDPN epitope recognized by LpMab- 21 includes a 
peptide sequence linked to sialic acid.
Epitope mapping of LpMab- 21
We expressed hPDPN deletion mutants in CHO- K1 cells 
(Fig. 7A). LpMab- 21 detected dN23, dN37, dN46, dN55, 
and dN64. In contrast, LpMab- 21 did not react with 
Figure 4. Flow cytometric analysis using LpMab- 21 to detect PDPN expression in human cancer cells. Human cell lines analyzed were as follows: 
mesothelioma, NCI- H226; oral squamous cell carcinomas, HSC- 2 and HSC- 4; lung squamous cell carcinoma, PC- 10; and osteosarcomas U- 2 OS and 
MG- 63. Cells were treated reacted with LpMab- 21 (A) 1 μg/mL; red), LpMab- 17 (B, 1 μg/mL; red), or PBS (A and B, black) for 30 min at 4°C, followed 
by treatment with anti- mouse IgG- Oregon green. Fluorescence data were acquired using a Cell Analyzer EC800. Geometric Mean was described.
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dN75, dN85, dN95, or dN105, indicating that the 
N- terminus of the epitope recognized by LpMab- 21 resides 
between hPDPN Thr65 and Val75 (Fig. 7B). All deletion 
mutants were detected, using the anti-MAP-tag mAb, 
PMab-1 (Fig. 7C).
Next, we generated stable CHO- S cell lines expressing 
the hPDPN point mutants T65A, T66A, T70A, S71A, 
S74A, T76A, T85A, S86A, and S88A (Fig. 8A). These 
mutants were chosen, because the epitope of LpMab- 21 
includes a sialylated O- glycan (Fig. 6) and starts between 
residues Thr65 and Val75 (Fig. 7). LpMab- 21 reacted 
with all transfectants, except for T76A (Fig. 8B). All 
point mutants targeting Ser/Thr residues were detected 
by LpMab- 17 (Fig. 8C). Together, these data support 
the conclusion that the epitope recognized by LpMab- 21 
includes sialic acid linked to PDPN Thr76.
Figure 5. Immunohistochemical analysis using LpMab- 21 to detect PDPN expression in human cancer tissues. Tissue sections were prepared from the 
human cancer tissues as follows: glioblastoma (GBM, A and E); oral squamous cell carcinoma (OSCC; B, D, F, and H); seminoma (SE, C and G). 
Sections were incubated (antigen retrieval omitted) with 1 μg/mL of LpMab- 21 (A–D), reacted with the Envision+ kit, color was developed using DAB, 
and samples were then counterstained with hematoxylin. Sections were stained with hematoxylin and eosin as well (E–H). Arrowheads: lymphatic 
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We used alanine scanning to localize the epitope rec-
ognized by LpMab- 21 near hPDPN Thr76. Thus, nine 
hPDPN point mutants (Ser74–Thr85) were transiently 
expressed in CHO- K1 cells. LpMab- 21 did not detect 
T76A, G77A, I78A, or R79A. In contrast, LpMab- 12, which 
recognizes an epitope comprising hPDPN Thr52, detected 
each point mutant (Fig. 9B), indicating that Thr76–Arg79 
is the minimum epitope recognized by LpMab- 21. We 
summarized and compared LpMab- 21 with the several 
anti- hPDPN mAbs (Table 2).
Table 1. Characterization of glycan- deficient or PDPN- knock out cells.
Cell name Parental cells Targeted genes Genom editing Deficient
PDIS- 1 HEK- 293T hsMgat1/GnT- 1 TALEN N- glycan
PDIS- 2 HEK- 293T PDPN CRISPR/Cas9 PDPN
PDIS- 6 LN319 PDPN CRISPR/Cas9 PDPN
PDIS- 9 CHO- S hsMgat1/GnT- 1 TALEN N- glycan
PDIS- 12 HEK- 293T hsMgat1/GnT- 1 TALEN N- glycan
PDIS- 14 CHO- S SLC35A1 CRISPR/Cas9 Sialic acid
PDIS- 22 HEK- 293T SLC35A1 CRISPR/Cas9 Sialic acid
Figure 6. Flow cytometric analysis using LpMab- 21 to detect hPDPN expression in sialic acid- deficient cells. CHO- S, CHO- S/hPDPN, PDIS- 9/hPDPN, and 
PDIS- 14/hPDPN cells were reacted with LpMab- 21 (A, 1 μg/mL; red), LpMab- 21 (B, 10 μg/mL; red), or LpMab- 17 (C, 1 μg/mL; red), or PBS (A, B, and 
C; black) for 30 min at 4°C, followed by treatment with anti- mouse IgG- Oregon green. Fluorescence data were acquired using a Cell Analyzer EC800. 
Geometric Mean was described.
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Figure 7. Epitope mapping of LpMab- 21 using deletion mutants of hPDPN. (A) Structures of hPDPN deletion dN23, dN37, dN46, dN55, dN64, dN75, 
dN85, dN95, dN105. (B, C) Each hPDPN deletion mutant was reacted with LpMab- 21 (B, 1 μg/mL; red), PMab- 1 (C, 1 μg/mL; red), or PBS (B and C, 
black) for 30 min at 4°C, followed by treatment with anti- mouse IgG- Oregon green (B) or anti- rat IgG- Oregon green (C). Fluorescence data were 
acquired using a Cell Analyzer EC800. Geometric Mean was described.
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Figure 8. Epitope mapping of LpMab- 21 using hPDPN- Ser/Thr point mutants. (A) Amino acid sequence of hPDPN encompassing Thr76. (B, C) Stable 
CHO- S transfectants expressing hPDPN point mutants T65A, T66A, T70A, S71A, S74A, T76A, T85A, S86A, and S88A were reacted with LpMab- 21 
(B, 1 μg/mL; red), LpMab- 17 (C, 1 μg/mL; red), or PBS (B and C; black) for 30 min at 4°C, followed by treatment with anti- mouse IgG- Oregon green. 
Fluorescence data were acquired using a Cell Analyzer EC800. Geometric Mean was described.
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Discussion
The anti- hPDPN mAb (NZ- 1) detects hPDPN with high 
specificity and sensitivity [6, 10, 25]. Moreover NZ- 1, 
which is also useful for detecting the podoplanin/aggrus 
(PA) epitope tag [49, 50], is efficiently internalized by 
glioma cell lines, accumulates in tumors in vivo, and is 
Figure 9. Epitope mapping of LpMab- 21, using point mutants of hPDPN. Nine hPDPN point Ser74–Thr85 point mutants were transiently expressed 
in CHO- K1 cells. Cells were reacted with LpMab- 21 (A, 1 μg/mL; red), LpMab- 12 (B, 1 μg/mL; red), or control PBS (A and B, black) for 30 min at 4°C, 
followed by treatment with anti- mouse IgG- Oregon green. Fluorescence data were acquired using a Cell Analyzer EC800. (C) Illustration of the 
epitope recognized by anti- hPDPN mAbs. Geometric Mean was described. PBS, phosphate- buffered saline.
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therefore a suitable candidate for therapy for malignant 
gliomas [5, 10]. Further, NZ- 1 inhibits tumor cell- induced 
platelet aggregation and tumor metastasis [23]. NZ- 1 
mediates antibody- dependent cellular cytotoxicity (ADCC) 
and complement- dependent cytotoxicity (CDC) against 
tumor cells that express hPDPN [51]. Moreover, NZ- 1 
is suitable for western blotting, flow cytometry, immu-
nohistochemistry, and immunoprecipitation [51]. 
However, NZ- 1 was produced using synthetic peptide [6]; 
therefore, further mAbs against hPDPN, especially anti- 
glycopeptide mAbs are necessary to investigate the structure 
and function of PDPN.
Previously, we developed the original technology to 
produce cancer- specific mAbs that detect cell type- specific 
posttranslational modifications of the same protein [30]. 
We used LN229/hPDPN cells as the immunogen to elicit 
novel anti- PDPN mAbs. We produced several clones includ-
ing LpMab- 2, LpMab- 3, and LpMab- 9 as anti- glycopeptide 
mAbs [30]. Recently, we further immunized mice with 
LN229/hPDPN cells to develop further anti- glycopeptide 
mAbs against human PDPN, and characterized several 
clones, including LpMab- 12 and LpMab- 19. In this study, 
we characterized another clone LpMab- 21, which detects 
many human cancer cell lines that express PDPN, such 
as those derived from glioblastomas, lung squamous cell 
carcinomas, oral squamous cell carcinomas, osteosarcomas, 
and malignant mesotheliomas. The isotypes of previously 
established anti- PDPN mAbs are IgG1 (seven clones) and 
IgG3 (one clone). However, the applications of mouse IgG3 
mAbs are limited because they often aggregate [52]. 
Moreover, mouse IgG1 and IgG3 isotypes do not induce 
ADCC or CDC. Therefore, we required chimeric mAbs 
using human IgG1 to investigate these activities [33]. 
LpMab- 21 (IgG2a subclass) could be used to investigate 
the function of anti- tumor activities in xenograft models 
because LpMab- 21 induced ADCC and CDC (data not 
shown).
Furthermore, we need several glycan- deficient cell lines 
such as sialic acid- deficient or N- glycan deficient cell lines 
to characterize those mAbs. In this study, we successfully 
produced several glycan- deficient cell lines such as sialic 
acid deficient (PDIS- 14 and PDIS- 22) or N- glycan deficient 
cell lines (PDIS- 1, PDIS- 9, and PDIS- 12), using CRISPR/
Cas9 and TALEN systems. Using those cell lines, we 
determined that the epitope of LpMab- 21 includes sialic 
acids, indicating that we can also investigate whether the 
epitope of novel mAbs against the other membrane pro-
teins possesses sialic acids or N- glycans.
We showed here that LpMab- 21 detected glioblastomas, 
oral cancers, and seminomas (Fig. 5) as well as normal 
cells such as lymphatic endothelial cells, basal epithelial cells 
of the esophagus, and myoepithelial cells of breast glands 
(Fig. 3). In contrast, LpMab- 21 did not react with the renal 
glomerulus or with type I alveolar cells of lung (Fig. 3), 
indicating that sialylation of hPDPN is tissue-specific.
In conclusion, LpMab- 21 shows promise for investigat-
ing the expression and function of hPDPN in cancers 
and normal tissues. Further, mAbs that recognize different 
epitopes of hPDPN should serve as powerful tools for 
identifying the function of hPDPN.
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Table 2. Characterization of anti- PDPN glycopeptide mAbs.
Anti- glycopeptide mAb Subclass Epitope CasMab/non- CasMab HC (LEC, T1a, POD)
O- glycan Pepitde
LpMab- 21 IgG2a, kappa Thr76 Thr76–Arg79 Non- CasMab positive for only LEC
LpMab- 2 IgG1, kappa Thr55/Ser56 Thr55–Leu64 CasMab negative
LpMab- 3 IgG1, kappa Thr76 Thr76–Glu81 Non- CasMab positive for LEC, T1a, POD
LpMab- 9 IgG1, kappa Thr25 Thr25–Asp30 Non- CasMab not applicable
LpMab- 12 IgG1, kappa Thr52 Asp49–Pro53 Non- CasMab positive for LEC, T1a, POD
LpMab- 19 IgG2b, kappa Thr76 Thr76–Arg79 Non- CasMab positive for LEC, T1a, POD
CasMab, cancer-specific mAb; IHC, immunohistochemical analysis; T1a, type I alveolar cells; POD, podocyte.
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Figure S1. Flow cytometric analysis, using LpMab- 21 
to detect hPDPN expression in sialic acid- deficient cells. 
HEK- 293T, PDIS- 1, PDIS- 12, and PDIS- 22 cells were 
reacted with LpMab- 21 (A, 1 μg/mL; red), or LpMab- 17 
(B, 1 μg/mL; red), or PBS (A and B; black) for 30 min 
at 4°C, followed by treatment with anti- mouse IgG- Oregon 
green. Fluorescence data were acquired using a Cell Analyzer 
EC800. 
